← Eichor
Condition: Malignant Tumor Synced from ClinicalTrials.gov · July 27, 2026

Recruiting studies: Malignant Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Guangzhou FineImmune Biotechnology Co., LTD. · NCT06942143APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT07489378ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06904378Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3 · 1 location(s) · Shanghai Bovax Biotechnology Co., Ltd. · NCT05027776PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06977074A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell
Phase 1 · 14 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07179679A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 22 location(s) · Sanofi · NCT05584670A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Phase 1 · 9 location(s) · PAQ Therapeutics, Inc. · NCT07300150DETECT: Target Volume for Rectal Endoluminal Radiation Boosting
Phase N/A · 3 location(s) · Maastricht Radiation Oncology · NCT04927897IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1 · 2 location(s) · TuHURA Biosciences, Inc. · NCT06940440Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Phase 1/Phase 2 · 2 location(s) · Nanjing Immunophage Biotech Co., Ltd · NCT06212076Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Phase 2 · 4 location(s) · University Hospital Heidelberg · NCT06456359Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Phase 3 · 19 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT04996017PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
Phase N/A · 4 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07089550FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients
NA · 1 location(s) · Amsterdam UMC, location VUmc · NCT06282562To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
NA · 1 location(s) · Yong Wha Moon · NCT07651124The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Phase N/A · 8 location(s) · Jasper Gerritsen · NCT06118723Development of New Diagnostic Tools in Capsule Endoscopy
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06152289Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05178472SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Phase N/A · 55 location(s) · Insel Gruppe AG, University Hospital Bern · NCT01039922Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 12 location(s) · Excyte Biopharma Ltd · NCT06580301Neurocognitive Function After Proton Therapy in Children and Adolescents
Phase N/A · 3 location(s) · Technische Universität Dresden · NCT04066465A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06475300Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
NA · 1 location(s) · Umeå University · NCT04612907A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Crossignal Therapeutics, Inc. · NCT06598007Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Phase 2 · 7 location(s) · Rutgers, The State University of New Jersey · NCT06518837NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations
Phase 1/Phase 2 · 17 location(s) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. · NCT07079475OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infi
Phase N/A · 28 location(s) · The Netherlands Cancer Institute · NCT06476119
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.